Investor relations
Cinclus Pharma
Investors
Cinclus Pharma is a Swedish clinical stage pharma company developing small molecules for the treatment of gastric acid related diseases. Our lead candidate linaprazan glurate is being developed for treatment of severe gastroesophageal reflux disease (GERD).
Latest financial reports |
| Year End Report 2024 |
| Interim Report Jan – Sept 2024 |
| Interim Report Jan–Jun 2024 |
| Årsredovisning Cinclus Pharma 2023 |
Financial calendar |
| Annual Report 2024 | 17 April 2025 | ||
| Q1 Report 2025 | 20 May 2025 | ||
| Annual General Meeting 2025 | 22 May 2025 | ||
| Q2 Report 2025 | 20 August 2025 | ||
| Q3 Report 2025 | 20 November 2025 |
